1124330-14-8

Basic information

• Product Name: 2-methoxy-4-(1-methylpiperidin-4-yl)aniline
• Synonyms: 2-methoxy-4-(1-methylpiperidin-4-yl)aniline
• CAS NO: 1124330-14-8
• Molecular Weight: 220.315
• Mol File: 1124330-14-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 342.8±42.0 °C(Predicted)
• Density: 1.059±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-methoxy-4-(1-methylpiperidin-4-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methoxy-4-(1-methylpiperidin-4-yl)aniline(1124330-14-8)
• EPA Substance Registry System: 2-methoxy-4-(1-methylpiperidin-4-yl)aniline(1124330-14-8)

Safety Data

• Hazardous Substances Data: 1124330-14-8(Hazardous Substances Data)

Upstream product

• 1246533-06-1 tert-butyl 4-(4-amino-3-methoxy-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylate 
• 59557-91-4 4-bromo-2-methoxyaniline 
• 454482-11-2 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl )-1,2,3,6-tetrahydropyridine 
• 1625678-62-7 4-(3-methoxy-4-nitrophenyl)-1-methyl-1,2,3,6-tetrahydropyridine 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 6627-53-8 1-chloro-3-methoxy-4-nitrobenzene 
• 1089280-53-4 tert-butyl 4-(4-amino-3-methoxyphenyl)piperidine-1-carboxylate 
• 1233145-65-7 4-(3-methoxy-4-nitro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1124330-13-7 tert-butyl N-[2-methoxy-4-(1-methyl-4-piperidyl)phenyl]carbamate 
• 103347-93-9 4-(3-methoxy-4-nitrophenyl)pyridine 
• 1692-15-5 4-pyridylboronic acid 

Downstream Products

• 1254783-30-6 C₂₆H₂₈ClN₅O₃ 
• 1233144-32-5 [2-methoxy-4-(1-methylpiperidin-4-yl)-phenyl][7-(2-methoxyphenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl]amine 
• 1625677-47-5 N-(3-(2-((2-methoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide 
• 1936529-65-5 3-(2-chloro-6-methylphenyl)-7-(2-methoxy-4-(1-methylpiperidin-4-yl)phenylamino)-1-(5-methoxypyridin-2-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one 
• 1346448-21-2 N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(1-methylpiperidin-4-yl)phenyl)acrylamide 
• 1346448-20-1 N₂-(5-amino-2-methoxy-4-(1-methylpiperidin-4-yl)phenyl)-5-chloro-N₄-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine 
• 1346448-19-8 5-chloro-N₄-(2-(isopropylsulfonyl)phenyl)-N₂-(2-methoxy-4-(1-methylpiperidin-4-yl)-5-nitrophenyl)pyrimidine-2,4-diamine 
• 1346448-18-7 2-methoxy-4-(1-methylpiperidin-4-yl)-5-nitroaniline 
• 1346448-17-6 N-(2-methoxy-4-(1-methylpiperidin-4-yl)-5-nitrophenyl)acetamide 
• 1346448-16-5 N-(2-methoxy-4-(1-methylpiperidin-4-yl)phenyl)acetamide 
• 1315513-78-0 7-Amino-2-[2-methoxy-4-(1-methylpiperid-4-yl)phenylamino]-5-oxo-8-phenyl-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide 

Relevant articles and documents

BICYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity

Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk neuroblastoma patients, mutation of ALK and amplification of MYCN. Starting from known dual polo-like kinase (PLK)-1-BRD4 inhibitor BI-2536, we employed structure-based design to redesign this series toward compounds with a dual ALK-BRD4 profile. These efforts led to compound (R)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((4-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5H)-one (16k) demonstrating improved ALK activity and significantly reduced PLK-1 activity, while maintaining BRD4 activity and overall kinome selectivity. We demonstrate the compounds' on-target engagement with ALK and BRD4 in cells as well as favorable broad kinase and bromodomain selectivity.

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors. This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clinical candidate brigatinib. A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addition to favorable ADME properties. Brigatinib displayed low nanomolar IC50s against native ALK and all tested clinically relevant ALK mutants in both enzyme-based biochemical and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC). Brigatinib represents the most clinically advanced phosphine oxide-containing drug candidate to date and is currently being evaluated in a global phase 2 registration trial.